<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016470</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-0916-CU</org_study_id>
    <nct_id>NCT01016470</nct_id>
  </id_info>
  <brief_title>Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease</brief_title>
  <official_title>Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could
      improve the progression disease, in patients with Parkinson's Disease (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Periodical measures of the clinical features with UPDRS will be done at the beginning, each
      three months until two years. Each group will be compare to evaluate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Periodical measures of the clinical features with Unified Parkinson Disease Rating Scale (UPDRS) will be done at the beginning, every three months until one year (end of the treatment)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hoehn-Yarh will be done at the beginning, every three months until one year (end of the treatment)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage levodopa will be done at the beginning, every three months until one year (end of the treatment)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Parkinson`s Disease</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VIUSID/ALZER. The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with early PD by UPDRS motor</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VIUSID/ALZER</intervention_name>
    <description>VIUSID/ALZER, 3 per day, oral, one year</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Viusid and Placebo Alzer, 3 per day, oral, one year</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical of PD, with the criteria of Brain Bank of London with early
             stage.

          -  Informed consent.

        Exclusion Criteria:

          -  Presence of another disease not well controlled.

          -  Patient with atypical features.

          -  Patient with advanced Parkinson`s disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Luis Guiroud, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Salvador Allende&quot; Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>&quot;Salvador Allende Hospital&quot;</name>
      <address>
        <city>Havana City</city>
        <state>Havana</state>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <link>
    <url>http://www.catalysis.es</url>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>May 2, 2012</last_update_submitted>
  <last_update_submitted_qc>May 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

